Drug discovery research collaboration is announced


Leica Microsystems and Definiens have announced a co-marketing agreement.

Leica Microsystems and Definiens have announced a co-marketing agreement.

Global precision optical system designer and producer Leica Microsystems will market their products with biomedical image analysis developer Definiens. Both firms will host educational events and workshops. Definiens Developer XD will analyze data created by Leica's confocal microscopes.

Thomas P. Heydler, CEO of Definiens, said: “Definiens and Leica Microsystems share a commitment to developing powerful imaging solutions that help researchers understand biological pathways faster and more accurately. This partnership will provide Leica customers with access to Definiens’ advanced image analysis software, enabling high-content screening that directly aids drug discovery efforts around the world.”

Dr Stefan Traeger, Managing Director of the Life Science Division of Leica Microsystems, said: “Together with Definiens, we look forward to the opportunity to make highly developed and future-proof high content screening solutions widely available for academic research as well. The combination of high-sensitivity confocal technology, miniaturized sample handling and reproducible evaluation with optimized data management is a sine qua non among drug discovery strategies and the analysis of their physiological relevance.”

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.